Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 17 | 2024 | 337 | 3.220 |
Why?
|
| Fluorine Radioisotopes | 11 | 2021 | 25 | 3.180 |
Why?
|
| Radiopharmaceuticals | 8 | 2018 | 196 | 1.860 |
Why?
|
| Etanidazole | 4 | 2015 | 4 | 1.840 |
Why?
|
| Hydrocarbons, Fluorinated | 4 | 2015 | 14 | 1.830 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2015 | 447 | 1.210 |
Why?
|
| Iodine Radioisotopes | 4 | 2019 | 134 | 1.110 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2018 | 55 | 1.110 |
Why?
|
| Glioma | 3 | 2018 | 294 | 1.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2022 | 32 | 0.980 |
Why?
|
| Herpesvirus 3, Human | 4 | 2012 | 40 | 0.970 |
Why?
|
| Halogenation | 2 | 2019 | 6 | 0.850 |
Why?
|
| para-Aminobenzoates | 1 | 2021 | 6 | 0.790 |
Why?
|
| Thymidine Kinase | 4 | 2012 | 30 | 0.770 |
Why?
|
| Pyrrolidines | 1 | 2021 | 59 | 0.760 |
Why?
|
| Osteosarcoma | 1 | 2022 | 161 | 0.740 |
Why?
|
| Trastuzumab | 2 | 2019 | 74 | 0.700 |
Why?
|
| Guanidine | 1 | 2019 | 17 | 0.690 |
Why?
|
| Benzoates | 1 | 2019 | 33 | 0.690 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 329 | 0.670 |
Why?
|
| Sulfonamides | 3 | 2016 | 318 | 0.620 |
Why?
|
| Benzeneacetamides | 1 | 2018 | 11 | 0.610 |
Why?
|
| Pyrimidine Nucleosides | 2 | 2007 | 6 | 0.590 |
Why?
|
| Radioisotopes | 3 | 2024 | 45 | 0.590 |
Why?
|
| Imidazoles | 1 | 2018 | 148 | 0.570 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2024 | 315 | 0.550 |
Why?
|
| Mice | 19 | 2023 | 11764 | 0.550 |
Why?
|
| Neoplasms | 4 | 2024 | 3041 | 0.540 |
Why?
|
| Tissue Distribution | 7 | 2019 | 293 | 0.530 |
Why?
|
| Animals | 26 | 2024 | 27380 | 0.520 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 217 | 0.490 |
Why?
|
| Cyclic N-Oxides | 1 | 2013 | 33 | 0.440 |
Why?
|
| Cell Line, Tumor | 10 | 2019 | 2558 | 0.430 |
Why?
|
| Triazines | 1 | 2013 | 53 | 0.430 |
Why?
|
| Mice, Nude | 4 | 2021 | 815 | 0.420 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 9 | 0.420 |
Why?
|
| Solid Phase Extraction | 2 | 2012 | 13 | 0.410 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2415 | 0.400 |
Why?
|
| Hypoxia | 2 | 2013 | 653 | 0.330 |
Why?
|
| Cell Hypoxia | 4 | 2014 | 170 | 0.330 |
Why?
|
| Biological Transport | 5 | 2016 | 401 | 0.320 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2007 | 36 | 0.300 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2007 | 3 | 0.290 |
Why?
|
| Nucleotides, Cyclic | 1 | 2007 | 12 | 0.290 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2007 | 89 | 0.290 |
Why?
|
| Cocaine | 1 | 2007 | 76 | 0.280 |
Why?
|
| Radiochemistry | 3 | 2016 | 5 | 0.270 |
Why?
|
| Humans | 23 | 2023 | 89367 | 0.250 |
Why?
|
| Genes, Reporter | 3 | 2012 | 275 | 0.240 |
Why?
|
| Pentanones | 1 | 2024 | 3 | 0.230 |
Why?
|
| Vanadium | 1 | 2024 | 13 | 0.230 |
Why?
|
| Hydroxybutyrates | 1 | 2024 | 27 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1121 | 0.230 |
Why?
|
| Rats | 6 | 2014 | 4041 | 0.230 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.220 |
Why?
|
| Antiviral Agents | 1 | 2007 | 478 | 0.220 |
Why?
|
| Brain | 3 | 2010 | 2285 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 470 | 0.210 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 413 | 0.210 |
Why?
|
| Carbonic Anhydrases | 2 | 2013 | 15 | 0.200 |
Why?
|
| Cell Line | 5 | 2019 | 2496 | 0.200 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 48 | 0.200 |
Why?
|
| Binding, Competitive | 1 | 2021 | 146 | 0.190 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 397 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 2364 | 0.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2013 | 981 | 0.170 |
Why?
|
| Antigens, Neoplasm | 2 | 2013 | 332 | 0.170 |
Why?
|
| Acylation | 1 | 2019 | 40 | 0.170 |
Why?
|
| Quality Control | 1 | 2019 | 117 | 0.170 |
Why?
|
| Carbon Radioisotopes | 3 | 2008 | 35 | 0.170 |
Why?
|
| Cicatrix | 1 | 2019 | 68 | 0.170 |
Why?
|
| Prostatic Neoplasms | 3 | 2023 | 1769 | 0.170 |
Why?
|
| Organotechnetium Compounds | 2 | 2010 | 11 | 0.170 |
Why?
|
| Isotope Labeling | 2 | 2016 | 52 | 0.160 |
Why?
|
| Peptides | 1 | 2022 | 648 | 0.160 |
Why?
|
| Single-Domain Antibodies | 1 | 2018 | 4 | 0.160 |
Why?
|
| CD3 Complex | 1 | 2018 | 134 | 0.150 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 255 | 0.150 |
Why?
|
| Heterografts | 1 | 2018 | 102 | 0.150 |
Why?
|
| Liver | 3 | 2019 | 1207 | 0.150 |
Why?
|
| Muscles | 1 | 2018 | 193 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 338 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2019 | 175 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 246 | 0.130 |
Why?
|
| Erythromycin | 1 | 2004 | 10 | 0.120 |
Why?
|
| Male | 9 | 2023 | 42423 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2018 | 501 | 0.120 |
Why?
|
| Disulfiram | 1 | 2014 | 8 | 0.120 |
Why?
|
| Chromatography, Liquid | 1 | 2004 | 106 | 0.120 |
Why?
|
| Copper | 1 | 2014 | 78 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 193 | 0.110 |
Why?
|
| Technetium | 1 | 2013 | 29 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 111 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2014 | 188 | 0.110 |
Why?
|
| Prodrugs | 1 | 2013 | 50 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 645 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 1266 | 0.110 |
Why?
|
| Cyclotrons | 1 | 2012 | 1 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2018 | 682 | 0.100 |
Why?
|
| HCT116 Cells | 1 | 2012 | 155 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1800 | 0.100 |
Why?
|
| Lentivirus | 2 | 2012 | 43 | 0.100 |
Why?
|
| Nitroimidazoles | 1 | 2011 | 8 | 0.090 |
Why?
|
| Transduction, Genetic | 2 | 2012 | 160 | 0.090 |
Why?
|
| Misonidazole | 1 | 2011 | 17 | 0.090 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 25 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2007 | 290 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2007 | 302 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 91 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2012 | 446 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2010 | 150 | 0.080 |
Why?
|
| Molecular Imaging | 1 | 2010 | 65 | 0.080 |
Why?
|
| Radiography | 1 | 2011 | 809 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 969 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 364 | 0.080 |
Why?
|
| Pyrans | 1 | 2008 | 10 | 0.080 |
Why?
|
| Lac Operon | 1 | 2008 | 47 | 0.080 |
Why?
|
| Naphthols | 1 | 2007 | 4 | 0.080 |
Why?
|
| Carboxylic Acids | 1 | 2007 | 17 | 0.070 |
Why?
|
| Female | 7 | 2019 | 46222 | 0.070 |
Why?
|
| Pregnancy, Animal | 1 | 2007 | 58 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1653 | 0.070 |
Why?
|
| Ligands | 1 | 2007 | 445 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 179 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 4143 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1552 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2007 | 1132 | 0.060 |
Why?
|
| Scandium | 1 | 2023 | 5 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2014 | 3386 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 1310 | 0.050 |
Why?
|
| Carbonic Anhydrase IX | 2 | 2013 | 11 | 0.050 |
Why?
|
| Kidney | 1 | 2007 | 1147 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2367 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2013 | 8245 | 0.040 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 9 | 0.040 |
Why?
|
| Glutaminase | 1 | 2019 | 12 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 39 | 0.040 |
Why?
|
| Glutamine | 1 | 2019 | 80 | 0.040 |
Why?
|
| Metabolomics | 1 | 2019 | 75 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2019 | 48 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 410 | 0.040 |
Why?
|
| Caproates | 1 | 2018 | 5 | 0.040 |
Why?
|
| Click Chemistry | 1 | 2018 | 5 | 0.040 |
Why?
|
| Single-Chain Antibodies | 1 | 2018 | 18 | 0.040 |
Why?
|
| Antibodies, Bispecific | 1 | 2018 | 26 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 96 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 370 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1489 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 751 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 44 | 0.030 |
Why?
|
| Esters | 1 | 2014 | 30 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 196 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 261 | 0.030 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2013 | 4 | 0.030 |
Why?
|
| Rhenium | 1 | 2013 | 3 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 123 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 176 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1767 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2012 | 38 | 0.030 |
Why?
|
| Nucleosides | 1 | 2012 | 22 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 2014 | 0.030 |
Why?
|
| Homeostasis | 1 | 2014 | 417 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 286 | 0.030 |
Why?
|
| Viral Load | 1 | 2012 | 145 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 727 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 490 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1224 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 120 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 105 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 640 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1528 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2010 | 273 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 24 | 0.020 |
Why?
|
| Octanols | 1 | 2007 | 1 | 0.020 |
Why?
|
| Buffers | 1 | 2007 | 26 | 0.020 |
Why?
|
| Pentetic Acid | 1 | 2007 | 25 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1717 | 0.020 |
Why?
|
| Necrosis | 1 | 2007 | 209 | 0.020 |
Why?
|
| Phosphates | 1 | 2007 | 160 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 313 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 153 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 353 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2759 | 0.020 |
Why?
|
| Fetus | 1 | 2007 | 232 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 661 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2007 | 370 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3012 | 0.010 |
Why?
|
| Middle Aged | 1 | 2019 | 25989 | 0.010 |
Why?
|
| Lung | 1 | 2007 | 1262 | 0.010 |
Why?
|
| Adult | 1 | 2019 | 26625 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3667 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 3018 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 5339 | 0.010 |
Why?
|